

References

S-11

1. Ewald N, Kloer H. Treatment options for severe hypertriglyceridemia (SHTG): the role of apheresis. *Clinical Research In Cardiology Supplements*. June 2012;7:31-35. Ipswich, MA.
2. Nakae H, Igarashi T, Tajimi K. Selective Plasma Exchange with Dialysis in Patients with Acute Liver Failure. *Therapeutic Apheresis and Dialysis*. October 2012;16(5):467-471.
3. Napoli C, Ambrosio G, Scarpato N, et al. Decrease low-density lipoprotein oxidation after repeated selective apheresis in homozygous familial. *American Heart Journal*. May 2012;133(5):585-595.
4. Hahn BH, McMahon MA, Wilkinson A, et al. American college of rheumatology guidelines for screening, treatment, and management of Lupus nephritis. *Arthritis Care and Research*. 2012; 64(6):797-808
5. Ramunni A, Petrarulo F, Grasso C, Papagni S, Brescia P. Acute and chronic effects of therapeutic apheresis. *Atherosclerosis. Supplements*. January 2013;14(1):83-87. Ipswich, MA.
6. Clinical outcomes, perfusion and vascular function in patients with refractory angina and raised lipoprotein (a), treated with lipoprotein apheresis. *ClinicalTrials.gov*. Identifier NCT01796912. October 2013.
7. Friley JL, Kaplan AA. Indications for therapeutic plasma exchange. Available from: *Up-To-Date*. Accessed March 2016.
8. Huang C, Chang C, Huang C, et al. Using oxidized low-density lipoprotein autoantibodies to predict restenosis after balloon angioplasty in patients with acute myocardial infarction. *Plos One*. October 2013;8(10):e74726.
9. Schrier S. Acquired pure red cell aplasia in the adult. *Up-To-Date*. October 28, 2013.
10. U.S. Food and Drug Administration. FDA approves new pediatric use for Liposorber *Apheresis System*. October 2013.
11. Friley J, Kaplan A. Therapeutic plasma exchange: Indications. Available from: *Up-to-Date*. Accessed December 2013.
12. Schwartz J, Winters J, Padmanadhan A, et al. Guidelines on the use of therapeutic apheresis in clinical practice—evidence-based approach from the writing committee of the American Society for Apheresis: The sixth special issue. *Journal of Clinical Apheresis*. June 2013;28(3):145-284.
13. Tavori H, Giunzioni I, Linton M, et al. loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. *Circulation Research*. Dec 2013;113(12):1290-1295.
14. Hertl M, Rudiger E. Management of refractory pemphigus vulgaris and pemphigus foliaceus. *Up-To-Date*.2013.
15. Diakoumakou O, Hatzigeorgiou G, Kolovou G, et al. Severe/Extreme Hypertriglyceridemia and LDL Apheretic Treatment: Review of the Literature, Original Findings. *Cholesterol*. 2014;2014:109263. Ipswich, MA.
16. National Comprehensive Cancer Network. *NCCN clinical practice guidelines in oncology: Multiple Myeloma*. Version 1. 2015.
17. Schwartz, J. Clinical Applications of Therapeutic Apheresis: An Evidence Based Approach. 6th Edition. *Journal of Clinical Apheresis*. 2013; 28(3):145-284.

19. Heigl, F. Clinical benefit of long-term lipoprotein apheresis in patients with severe hypercholesterolemia or Lp(a)-hyperlipoproteinemia with progressive cardiovascular disease. *Clin Res Cardiol Suppl.* 2015;10:8–13.
20. Varga, V. Impact of selective LDL apheresis on serum chemerin levels in patients with hypercholesterolemia. *Lipids in Health and Disease.* 2016; 15:1-7.
21. Winters, J. National Heart, Lung, and Blood Institute State of the Science Symposium in Therapeutic Apheresis—Therapeutic Apheresis in Cardiovascular Disease. *Journal of Clinical Apheresis.* 2015; 30: 183-187.
22. Su Y, Chiu W, Hsu C, Chen J, Ng H. Lower In-Hospital Mortality with Plasma Exchange than Plasmapheresis in a Subgroup Analysis of 374 Lupus Patients. *Biomed Research International.* May 2, 2018;:1-8. Accessed July 9, 2018.